The prophylactic value of TNF-α inhibitors against retinal cell apoptosis and optic nerve axon loss after corneal surgery or trauma.
TNF-α antibodies
biologics
glaucoma
inflammation
sub-conjunctival
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
revised:
13
09
2023
received:
13
03
2023
accepted:
18
09
2023
medline:
7
10
2023
pubmed:
7
10
2023
entrez:
7
10
2023
Statut:
aheadofprint
Résumé
Late secondary glaucoma is an often-severe complication after acute events like anterior segment surgery, trauma and infection. TNF-α is a major mediator that is rapidly upregulated, diffusing also to the retina and causes apoptosis of the ganglion cells and degeneration of their optic nerve axons (mediating steps to glaucomatous damage). Anti-TNF-α antibodies are in animals very effective in protecting the retinal cells and the optic nerve-and might therefore be useful prophylactically against secondary glaucoma in future such patients. Here we evaluate (1) toxicity and (2) efficacy of two TNF-α inhibitors (adalimumab and infliximab), in rabbits by subconjunctival administration. For drug toxicity, animals with normal, unburned corneas were injected with adalimumab (0.4, 4, or 40 mg), or infliximab (1, 10, or 100 mg). For drug efficacy, other animals were subjected to alkali burn before such injection, or steroids (for control). The rabbits were evaluated clinically with slit lamp and photography, electroretinography, optical coherence tomography, and intraocular pressure manometry. A sub-set of eyes were stained ex vivo after 3 days for retinal cell apoptosis (TUNEL). In other experiments the optic nerves were evaluated by paraphenylenediamine staining after 50 or 90 days. Loss of retinal cells and optic nerve degeneration were quantified. Subconjunctival administration of 0.4 mg or 4.0 mg adalimumab were well tolerated, whereas 40.0 mg was toxic to the retina. 1, 10, or 100 mg infliximab were also well tolerated. Analysis of the optic nerve axons after 50 days confirmed the safety of 4.0 mg adalimumab and of 100 mg infliximab. For efficacy, 4.0 mg adalimumab subconjunctivally in 0.08 mL provided practically full protection against retinal cell apoptosis 3 days following alkali burn, and infliximab 100 mg only slightly less. At 90 days following burn injury, control optic nerves showed about 50% axon loss as compared to 8% in the adalimumab treatment group. Subconjunctival injection of 4.0 mg adalimumab in rabbits shows no eye toxicity and provides excellent neuroprotection, both short (3 days) and long-term (90 days). Our total. accumulated data from several of our studies, combined with the present paper, suggest that corneal injuries, including surgery, might benefit from routine administration of anti-TNF-α biologics to reduce inflammation and future secondary glaucoma.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Late secondary glaucoma is an often-severe complication after acute events like anterior segment surgery, trauma and infection. TNF-α is a major mediator that is rapidly upregulated, diffusing also to the retina and causes apoptosis of the ganglion cells and degeneration of their optic nerve axons (mediating steps to glaucomatous damage). Anti-TNF-α antibodies are in animals very effective in protecting the retinal cells and the optic nerve-and might therefore be useful prophylactically against secondary glaucoma in future such patients. Here we evaluate (1) toxicity and (2) efficacy of two TNF-α inhibitors (adalimumab and infliximab), in rabbits by subconjunctival administration.
METHODS
METHODS
For drug toxicity, animals with normal, unburned corneas were injected with adalimumab (0.4, 4, or 40 mg), or infliximab (1, 10, or 100 mg). For drug efficacy, other animals were subjected to alkali burn before such injection, or steroids (for control). The rabbits were evaluated clinically with slit lamp and photography, electroretinography, optical coherence tomography, and intraocular pressure manometry. A sub-set of eyes were stained ex vivo after 3 days for retinal cell apoptosis (TUNEL). In other experiments the optic nerves were evaluated by paraphenylenediamine staining after 50 or 90 days. Loss of retinal cells and optic nerve degeneration were quantified.
RESULTS
RESULTS
Subconjunctival administration of 0.4 mg or 4.0 mg adalimumab were well tolerated, whereas 40.0 mg was toxic to the retina. 1, 10, or 100 mg infliximab were also well tolerated. Analysis of the optic nerve axons after 50 days confirmed the safety of 4.0 mg adalimumab and of 100 mg infliximab. For efficacy, 4.0 mg adalimumab subconjunctivally in 0.08 mL provided practically full protection against retinal cell apoptosis 3 days following alkali burn, and infliximab 100 mg only slightly less. At 90 days following burn injury, control optic nerves showed about 50% axon loss as compared to 8% in the adalimumab treatment group.
CONCLUSIONS
CONCLUSIONS
Subconjunctival injection of 4.0 mg adalimumab in rabbits shows no eye toxicity and provides excellent neuroprotection, both short (3 days) and long-term (90 days). Our total. accumulated data from several of our studies, combined with the present paper, suggest that corneal injuries, including surgery, might benefit from routine administration of anti-TNF-α biologics to reduce inflammation and future secondary glaucoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : R01 EY013124
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY021558
Pays : United States
Informations de copyright
© 2023 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Aldave, A.J., Rudd, J.C., Cohen, E.J., Rapuano, C.J. & Laibson, P.R. (2000) The role of glaucoma therapy in the need for repeat penetrating keratoplasty. Cornea, 19, 772-776.
Ali, M.H., Dikopf, M.S., Finder, A.G., Aref, A.A., Vajaranant, T. & de la Cruz, J. (2018) Assessment of glaucomatous damage after Boston Keratoprosthesis implantation based on digital planimetric quantification of visual fields and optic nerve head imaging. Cornea, 37, 602-608.
Al-Mahmood, A.M., Al-Swailem, S.A. & Edward, D.P. (2012) Glaucoma and corneal transplant procedures. Journal of Ophthalmology, 2012, 1-9.
Ayyala, R.S. (2000) Penetrating keratoplasty and glaucoma. Survey of Ophthalmology, 45, 91-105.
Baltaziak, M., Chew, H.F., Podbielski, D.W. & Ahmed, I.I.K. (2018) Glaucoma after corneal replacement. Survey of Ophthalmology, 63, 135-148.
Becker, B. & Shaffer, R.N. (1961) Classification of the glaucomas. In: Diagnosis and therapy of the Glaucomas. St. Louis: Mosby, pp. 15-20.
Cade, F., Grosskreutz, C.L., Tauber, A. & Dohlman, C.H. (2011) Glaucoma in eyes with severe chemical burn, before and after keratoprosthesis. Cornea, 30, 1322-1327.
Cade, F., Paschalis, E.I., Regatieri, C.V., Vavvas, D.G., Dana, R. & Dohlman, C.H. (2014) Alkali burn to the eye: protection using TNF-alpha inhibition. Cornea, 33, 382-389.
Chen, X., Lei, F., Zhou, C., Chodosh, J., Wang, L., Huang, Y. et al. (2020) Glaucoma after ocular surgery or trauma: the role of infiltrating monocytes and their response to cytokine inhibitors. The American Journal of Pathology, 190(10), 2056-2066.
Ciralsky, J., Papaliodis, G.N., Foster, C.S., Dohlman, C.H. & Chodosh, J. (2010) Keratoprosthesis in autoimmune disease. Ocular Immunology and Inflammation, 18, 275-280.
Crnej, A., Omoto, M., Dohlman, T.H., Gonzalez-Andrades, M., Paschalis, E.I. & Cruzat, A. (2016) Effect of penetrating keratoplasty and Keratoprosthesis implantation on the posterior segment of the eye. Investigative Ophthalmology & Visual Science, 57, 1643-1648.
Crnej, A., Paschalis, E.I., Salvador-Culla, B., Tauber, A., Drnovsek-Olup, B., Shen, L.Q. et al. (2014) Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea, 33, 349-354.
Dana, M.R., Moyes, A.L., Gomes, J.A., Rosheim, K.M., Schaumberg, D.A. & Laibson, P.R. (1995) The indications for and outcome in pediatric keratoplasty. A multicenter study. Ophthalmology, 102(8), 1129-1138.
Dohlman, C. (2022) The Boston Keratoprosthesis-the first 50 years: some reminiscences. Annual Review of Vision Science, 8(1), 1-32.
Dohlman, C.H., Cade, F., Regatieri, C.V., Zhou, C., Lei, F., Crnej, A. et al. (2018) Chemical burns of the eye: the role of retinal injury and new therapeutic possibilities. Cornea, 37(2), 248-251.
Dohlman, C.H., Dudenhoefer, E.J., Khan, B.F. & Dohlman, J.G. (2002) Corneal blindness from end-stage Sjögren's syndrome and graft-versus-host disease. In: Sullivan, D.A., Stern, M.E., Tsubota, K., Dartt, D.A., Sullivan, R.M. & Bromberg, B.B. (Eds.) Lacrimal gland, tear film, and dry eye syndromes 3: basic science and clinical relevance part B. Boston: Springer, pp. 1335-1338.
Dohlman, C.H., Robert, M.C. & Paschalis, E.I. (2020) Treatment of chemical burn to the eye: a changing picture. In: Colby, K. & Dana, R. (Eds.) Foundations of corneal disease: past, present and future. Denver, CO: Springer International Publishing, pp. 109-119.
Dohlman, C.H., Zhou, C., Lei, F., Cade, F., Regatieri, C.V., Crnej, A. et al. (2019) Glaucoma after corneal trauma or surgery-a rapid, inflammatory, IOP-independent pathway. Cornea, 38, 1589-1594.
Dohlman, J.G., Foster, C.S. & Dohlman, C.H. (2009) Boston Keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis. Digital Journal of Ophthalmology, 15, 5-8.
Doren, G.S., Cohen, E.J., Brady, S.E., Arentsen, J.J. & Laibson, P.R. (1990) Penetrating keratoplasty after ocular trauma. American Journal of Ophthalmology, 110, 408-411.
Dubey, S., Jain, K., Mukherjee, S., Sharma, N., Pegu, J., Gandhi, M. et al. (2019) Current profile of secondary glaucoma in a Northern India tertiary eye care hospital. Ophthalmic Epidemiology, 26, 200-207.
Foulks, G.N. (1987) Glaucoma associated with penetrating keratoplasty. Ophthalmology, 94(7), 871-874.
Geoffrion, D. & Harissi-Dagher, M. (2021) Glaucoma risk factors and outcomes following Boston Keratoprosthesis type 1 surgery. American Journal of Ophthalmology, 226, 56-67.
Giansanti, F., Ramazzotti, M., Vannozzi, L., Rapizzi, E., Fiore, T., Iaccheri, B. et al. (2008) A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Investigative Ophthalmology & Visual Science, 49(3), 1151-1156.
Giganti, M., Beer, P.M., Lemanski, N., Hartman, C., Schartman, J. & Falk, N. (2010) Adverse events after intravitreal infliximab (Remicade). Retina, 30(1), 71-80.
Gong, H., Ren, J., Zheng, B., Huang, X., Liao, Y. & Zhou, Y. (2021) The profile of secondary glaucoma in China: a study of over 10,000 patients. Journal of Glaucoma, 30, 895-901.
Haddadin, R.I. & Chodosh, J. (2014) Corneal transplantation and glaucoma. Seminars in Ophthalmology, 29, 380-396.
Harissi-Dagher, M. & Dohlman, C.H. (2008) The Boston Keratoprosthesis in severe ocular trauma. Canadian Journal of Ophthalmology, 43, 165-169.
Harwerth, R.S., Carter-Dawson, L., Smith, E.L., III, Barnes, G., Holt, W.F. & Crawford, M.L. (2004) Neural losses correlated with visual losses in clinical perimetry. Investigative Ophthalmology & Visual Science, 45, 3152-3160.
Huang, Y., Yuan, M., Duan, F., Yang, Y., Lou, B. & Lin, X. (2022) Inhibition of endoplasmic reticulum stress by 4-phenylbutyrate alleviates retinal inflammation and the apoptosis of retinal ganglion cells after ocular alkali burn in mice. Inflammation Research, 71, 577-590.
Irvine, A.R. & Kaufman, H.E. (1969) Intraocular pressure following penetrating keratoplasty. American Journal of Ophthalmology, 68(5), 835-844.
Iyer, G., Srinivasan, B., Agarwal, S., Shetty, R., Krishnamoorthy, S., Balekudaru, S. et al. (2015) Glaucoma in modified osteo-odonto-keratoprosthesis eyes: role of additional stage 1A and Ahmed glaucoma drainage device-technique and timing. American Journal of Ophthalmology, 159, 482-489.
Kamyar, R., Weizer, J.S., de Paula, F.H., Stein, J.D., Moroi, S.E., John, D. et al. (2012) Glaucoma associated with Boston type I keratoprosthesis. Cornea, 31, 134-139.
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L. & Hanzatian, D.K. (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology, 131(2), 308-316.
Kim, H., Robinson, M.R., Lizak, M.J., Tansey, G., Lutz, R.J., Yuan, P. et al. (2004) Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Investigative Ophthalmology & Visual Science, 45(8), 2722-2731.
Kim, S.H., Csaky, K.G., Wang, N.S. & Lutz, R.J. (2008) Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharmaceutical Research, 25(3), 512-520.
Kompa, S., Redbrake, C., Hilgers, C., Wüstemeyer, H., Schrage, N. & Remky, A. (2005) Effect of different irrigating solutions on aqueous humour pH changes, intraocular pressure and histological findings after induced alkali burns. Acta Ophthalmologica Scandinavica, 83, 467-470.
Kuckelkorn, R., Keller, G.K. & Redbrake, C. (2001) Glaucoma after extremely severe chemical and thermal eye burns. Surgical possibilities. Der Ophthalmologe, 98, 1149-1156.
Kumar, R.S., Tan, D.T., Por, Y.M., Oen, F.T., Hoh, S.T., Parthasarathy, A. et al. (2009) Glaucoma management in patients with osteo-odonto-keratoprosthesis (OOKP): the Singapore OOKP study. Journal of Glaucoma, 18, 354-360.
Lang, Y., Zemel, E., Miller, B. & Perlman, I. (2007) Retinal toxicity of intravitreal kenalog in albino rabbits. Retina, 27(6), 778-788.
Li, K.X., Durrani, A.F., Zhou, Y., Zhao, P.Y., Tannen, B.L., Mian, S.I. et al. (2022) Outcomes of penetrating keratoplasty after open globe injury. Cornea, 41, 1345-1352.
Liesenborghs, I., Schouten, J., Berendschot, T., Beckers, H.J.M., Nuijts, R., Visser, N. et al. (2020) Risk factors for the development of ocular hypertension after keratoplasty: a systematic review. Cornea, 39, 394-402.
Lin, M.P., Eksioglu, U., Mudumbai, R.C., Slabaugh, M.A. & Chen, P.P. (2012) Glaucoma in patients with ocular chemical burns. American Journal of Ophthalmology, 154, 481-485.
Madigan, M.C., Sadun, A.A., Rao, N.S., Dugel, P.U., Tenhula, W.N. & Gill, P.S. (1996) Tumor necrosis factor-alpha (TNF-alpha)-induced optic neuropathy in rabbits. Neurological Research, 18(2), 176-184.
Mascelli, M.A., Zhou, H., Sweet, R., Getsy, J., Davis, H.M., Graham, M. et al. (2007) Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. Journal of Clinical Pharmacology, 47(5), 553-565.
Mélik Parsadaniantz, S., Réaux-le Goazigo, A., Sapienza, A., Habas, C. & Baudouin, C. (2020) Glaucoma: a degenerative optic neuropathy related to neuroinflammation? Cell, 9(3), 535.
Miyamoto, F., Sotozono, C., Ikeda, T. & Kinoshita, S. (1998) Retinal cytokine response in mouse alkali-burned eye. Ophthalmic Research, 30, 168-171.
Netland, P.A., Terada, H. & Dohlman, C.H. (1998) Glaucoma associated with keratoprosthesis. Ophthalmology, 105, 751-757.
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K. et al. (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Investigative Ophthalmology & Visual Science, 50(10), 4807-4813.
Panda-Jonas, S., Jonas, J.B., Jakobczyk, M. & Schneider, U. (1994) Retinal photoreceptor count, retinal surface area, and optic disc size in normal human eyes. Ophthalmology, 101(3), 519-523.
Paschalis, E.I., Taniguchi, E.V., Chodosh, J., Pasquale, L.R., Colby, K. & Dohlman, C.H. (2019) Blood levels of tumor necrosis factor alpha and its type 2 receptor are elevated in patients with Boston type I Keratoprosthesis. Current Eye Research, 44, 599-606.
Paschalis, E.I., Zhou, C., Lei, F., Scott, N., Kapoulea, V., Robert, M.C. et al. (2017) Mechanisms of retinal damage after ocular alkali burns. The American Journal of Pathology, 187(6), 1327-1342.
Quigley, H.A. (1999) Neuronal death in glaucoma. Progress in Retinal and Eye Research, 18, 39-57.
Quigley, H.A. & Broman, A.T. (2006) The number of people with glaucoma worldwide in 2010 and 2020. The British Journal of Ophthalmology, 90, 262-267.
Quigley, H.A., Dunkelberger, G.R. & Green, W.R. (1989) Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. American Journal of Ophthalmology, 107(5), 453-464.
Ramsay, E., Hagström, M., Vellonen, K.S., Boman, S., Toropainen, E. & del Amo, E.M. (2019) Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation. European Journal of Pharmaceutics and Biopharmaceutics, 143, 18-23.
Ranta, V.P., Mannermaa, E., Lummepuro, K., Subrizi, A., Laukkanen, A. & Antopolsky, M. (2010) Barrier analysis of periocular drug delivery to the posterior segment. Journal of Controlled Release, 148(1), 42-48.
Robert, M.C., Črnej, A., Shen, L.Q., Papaliodis, G.N., Dana, R., Foster, C.S. et al. (2017) Infliximab after Boston Keratoprosthesis in Stevens-Johnson syndrome: an update. Ocular Immunology and Inflammation, 25, 413-417.
Robert, M.C., Frenette, M., Zhou, C., Yan, Y., Chodosh, J., Jakobiec, F.A. et al. (2016) A drug delivery system for Administration of Anti-TNF-alpha antibody. Translational Vision Science & Technology, 5, 11.
Roh, M., Zhang, Y., Murakami, Y., Thanos, A., Lee, S.C. & Vavvas, D.G. (2012) Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One, 7(7), e40065.
Rosenfeld, P.J. & Goodman, K.W. (2009) When is off-label drug use in the patient's best interest? American Journal of Ophthalmology, 147(5), 761-763.
Rumelt, S., Bersudsky, V., Blum-Hareuveni, T. & Rehany, U. (2002) Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea, 21, 759-765.
Subrizi, A., Del Amo, E.M., Korzhikov-Vlakh, V., Tennikova, T., Ruponen, M. & Urtti, A. (2019) Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discovery Today, 24(8), 1446-1457.
Suleiman, Y., Amm, M., Duncker, G.I.W. & Nölle, B. (2004) Prognose von Korneatransplantationen nach Bulbusperforation. Klinische Monatsblätter für Augenheilkunde, 221, 658-673.
Talajic, J.C., Agoumi, Y., Gagne, S., Moussally, K. & Harissi-Dagher, M. (2012) Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery. American Journal of Ophthalmology, 153, 267-274.e261.
Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., Charonis, A., Agrogiannis, G., Kavantzas, N. et al. (2009) Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefe's Archive for Clinical and Experimental Ophthalmology, 247(2), 273-281.
Thoft, R.A., Gordon, J.M. & Dohlman, C.H. (1974) Glaucoma following keratoplasty. Transactions-American Academy of Ophthalmology and Otolaryngology, 78, 352-364.
Thylefors, B. & Négrel, A.D. (1994) The global impact of glaucoma. Bulletin of the World Health Organization, 72(3), 323-326.
Tsai, J.H., Derby, E., Holland, E.J. & Khatana, A.K. (2006) Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea, 25, 530-532.
Tsilimbaris, M., Diakonis, V.F., Naoumidi, I., Charisis, S., Kritikos, I., Chatzithanasis, G. et al. (2009) Evaluation of potential retinal toxicity of adalimumab (Humira). Graefe's Archive for Clinical and Experimental Ophthalmology, 247(8), 1119-1125.
Vellonen, K.S., Soini, E.M., del Amo, E.M. & Urtti, A. (2016) Prediction of ocular drug distribution from systemic blood circulation. Molecular Pharmaceutics, 13(9), 2906-2911.
Wei, X., Cho, K.S., Thee, E.F., Jager, M.J. & Chen, D.F. (2019) Neuroinflammation and microglia in glaucoma: time for a paradigm shift. Journal of Neuroscience Research, 97, 70-76.
Weinreb, R.N., Aung, T. & Medeiros, F.A. (2014) The pathophysiology and treatment of glaucoma: a review. Jama, 311, 1901-1911.
Wiggs, J.L. (2015) Glaucoma genes and mechanisms. Progress in Molecular Biology and Translational Science, 134, 315-342.
Williams, P.A., Marsh-Armstrong, N. & Howell, G.R. (2017) Neuroinflammation in glaucoma: a new opportunity. Experimental Eye Research, 157, 20-27.
Wu, S. & Xu, J. (2017) Incidence and risk factors for post-penetrating keratoplasty glaucoma: a systematic review and meta-analysis. PLoS One, 12, e0176261.
Yaghouti, F., Nouri, M., Abad, J.C., Power, W.J., Doane, M.G. & Dohlman, C.H. (2001) Keratoprosthesis: preoperative prognostic categories. Cornea, 20, 19-23.
Yu, S.Y., Damico, F.M., Viola, F., D'Amico, D.J. & Young, L.H. (2006) Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina, 26(5), 531-536.
Yuan, L. & Neufeld, A.H. (2000) Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia, 32(1), 42-50.
Zhou C, Singh A, Qian G, Wolkow N, Dohlman CH, Vavvas DG, Chodosh J & Paschalis EI (2020): Microporous drug delivery system for sustained Anti-VEGF delivery to the eye. Trans Vis Sci Tech. 9(8): 5.
Zhou, C., Lei, F., Mittermaier, M., Ksander, B., Dana, R., Dohlman, C.H. et al. (2023) Opposing roles of blood-borne monocytes and tissue-resident macrophages in limbal stem cell damage after ocular injury. Cells, 12(16), 2089.
Zhou, C., Lei, F., Sharma, J., Hui, P.C., Wolkow, N., Dohlman, C.H. et al. (2023) Sustained inhibition of VEGF and TNF-α achieves multi-ocular protection and prevents formation of blood vessels after severe ocular trauma. Pharmaceutics, 15(8), 2059.
Zhou, C., Robert, M.C., Kapoulea, V., Lei, F., Stagner, A.M., Jakobiec, F.A. et al. (2017) Sustained subconjunctival delivery of infliximab protects the cornea and retina following alkali burn to the eye. Investigative Ophthalmology & Visual Science, 58, 96-105.